Molecular Medicine Tri-conference Plenary Session


Plenary Keynote Introductions


MONDAY, FEBRUARY 16


5:00 – 6:00 pm

Plenary Session Introduction:

Robert Penny, M.D., Ph.D., CEO, Paradigm

Integrating the Digital Universe of Data with Consumer-Driven Mobile Apps and Large-Scale Panomics Data to Better Understand, Treat, and Prevent Disease

Eric SchadtEric Schadt, Ph.D., Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences; Jean C. and James W. Crystal Professor of Genomics, Icahn School of Medicine at Mount Sinai

The digital universe of data continues to grow at an exponential pace, now comprising more than 1 zettabyte of useable data. Contributing to this big data revolution are panomic technologies, which have made possible the routine sequencing of whole genomes and transcriptomes, and wearable and implantable sensors that make the acquisition of real-time physiologic data across many dimensions a reality in populations of individuals. With extensive molecular, cellular, and physiologic data generated on individuals in a longitudinal fashion, the potential exists to characterize the health of an individual at a far deeper level than has been possible before. Better characterization of an individual’s health will lead to more precise diagnoses, treatments, and preventative strategies for disease at a highly personalized level. Towards this end, we have developed a predictive, multiscale framework that enables us to understand the health of an individual at the molecular, cellular, organ, organism and community scales so that we can better diagnose, treat, and prevent disease.

Biographical Profile:
Eric Schadt, Ph.D., is Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai. Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. He is known for calling for a shift in molecular biology toward a network-oriented view of living systems to complement the reductionist, single-gene approaches that currently dominate biology in order to more accurately model the complexity of biological systems. He has published more than 200 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from University of California, Davis, and his Ph.D. in bio-mathematics from University of California, Los Angeles (requiring Ph.D. candidacy in molecular biology and mathematics).  


TUESDAY, FEBRUARY 17


8:00 – 9:00 am

Plenary Session Introduction:

Peter Heseltine, CMO, Singulex, Inc.

The Dawn of a New Research Model: The Case for Parent - Clinician - Researcher Collaboration

Matt WilseyMatt Wilsey, President, Grace Wilsey Foundation

There are over 7,000 known rare diseases that affect an estimated 30 million Americans and 350 million people worldwide. The number of diseases with a known genetic cause is going to increase rapidly with next generation sequencing. Science is not equipped to handle the explosion. Reduced government funding has exacerbated the problem. Science will have trouble understanding and treating these diseases quickly and cost effectively using the historical model. A new approach is needed. One based on parent, clinician, and researcher collaboration. This presentation will propose the “NGLY1 Model”. NGLY1 Deficiency is a complex and devastating neuromuscular disease that affects less than 50 confirmed patients globally. An individual family personally affected by NGLY1 researched, recruited, and assembled a global team of 40 researchers across 10 international centers during the last 18 months. The level of speed and collaboration is unparalleled. The team represents the very best in multiple fields akin to the “Manhattan Project”. This talk will explain how this strategy can be applied to both rare and common diseases for faster, cheaper, and more comprehensive disease understanding and treatment.

Biographical Profile:
Matt is a Silicon Valley angel investor and advisor. His investments include Nimble Storage, Practice Fusion, Pintrest, Virtual Instruments, Bonobos, LYFE Kitchen, Caveman Foods, Frontier Snacks, Juicero, Rinse, Moment, Tout, Pinrose, Interior Define, Gear Launch, and Weddington Way. In addition to consumer products and services, Matt invests in and advocates for biomedical research, drug development, and genetic sequencing technologies. Before moving to the investment side, he spent many years as a front-line operator. Most recently, Matt was Co-Founder and Chief Revenue Officer of CardSpring, a payment infrastructure company that was acquired by Twitter. Previously, Matt ran West coast sales and business development for Howcast.com. He was responsible for building Howcast’s instructional content library, distribution network, and strategic relationships. Before Howcast, Matt worked for Kohlberg Kravis Roberts (KKR) on the Capital Markets team focused on new product development, capital raising, and investor relations. Prior to that, Matt spent five years as Co-Founder and Vice President of Business Development at Zazzle.com, where he was responsible for all content and distribution deals. He started his career serving in various roles at the White House and the Department of Defense. Matt became a rare disease hunter and advocate after his daughter, Grace, was born with NGLY1 Deficiency. He has since funded over 40 scientists at 10 medical centers in 3 countries with the sole purpose of treating the disease. Matt holds a B.A. from Stanford University and a M.B.A. from Stanford's Graduate School of Business. Matt sits on the Board of Directors of the Grace Wilsey Foundation where he is also President, Global Genes, The Lucile Packard Foundation for Children’s Health, the EveryLife Foundation for Rare Diseases, and Perlstein Lab.
 


TUESDAY, FEBRUARY 17


4:10 – 5:00 PM

Join us for this complimentary reception and casually network with other delegates, exhibitors, sponsors, poster presenters, and speakers in an informal, fun setting. Cocktails and light hors d’oeuvres will be served.


WEDNESDAY, FEBRUARY 18


8:00 – 9:45 am

Plenary Session Panel: Emerging Technologies and Industry Perspectives

Panelists:

Bernard Andruss, Ph.D., Vice President, CDx Development and Regulatory Affairs, Asuragen, Inc.

Yuling Luo, Ph.D., CEO and Founder, Advanced Cell Diagnostics

Rudi Pauwels, Ph.D., Founder, CEO & Executive Chairman, Biocartis

Michael Powell, Ph.D., CSO, DiaCarta,Inc.

Pawan Singh, Director, Workflow Solutions, Executive Management Leica Biosystems

Joe Beechman, Ph.D., Senior Vice President, R&D, NanoString Technologies

Lynn Zieske, Ph.D., Principal Scientist, Life Science, Singulex, Inc.

Gavin Coney, Senior Director,Services Strategy, Intellectual Property & Science, Thomson Reuters

 

Moderator:

Michael Roehrl, M.D., Ph.D., Associate Professor of Pathology, University of Toronto

Sponsored by:

Advanced Cell Diagnostics 

Asuragen 

Biocartis 

DiaCarta  

Leica Biosystems 

NanoString 

Singulex 

 Thomson Reuters  

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 Brochure cover 

Premier Sponsors:

Abbott Molecular 

 

Elsevier    


 IBM 

Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large